2026-03-24 20:34:46
NRX Pharmaceuticals, Inc. Announces Approval of Amendment to Omnibus Incentive Plan at 2025 Annual Meeting
Expected Stock impact: Slightly Positive
On March 23, 2026, NRX Pharmaceuticals, Inc. held its 2025 Annual Meeting of Stockholders, where significant corporate governance decisions were made. The stockholders approved Amendment No. 1 to the Omnibus Incentive Plan, which increases the annual 'evergreen' share reserve. This amendment allows for an increase in the number of shares available for issuance under the plan, from a maximum of 1% of the total shares outstanding to a new cap of 3,187,234 shares or 5% of the total shares outstanding, whichever is lesser. This change is expected to enhance the company's ability to attract and retain talent through equity compensation, which is crucial for its operational strategy moving forward. The board of directors had previously approved this amendment, contingent upon stockholder approval, which has now been achieved. The results of the voting showed strong support for the proposal, indicating confidence among shareholders in the company's strategic direction. Additionally, the meeting included the election of two Class I directors, Chaim Hurvitz and Michael Taylor, who will serve until the 2028 annual meeting. The stockholders also ratified the appointment of Weinberg & Company, P.A. as the independent registered public accounting firm for the fiscal year ending December 31, 2025. Overall, the outcomes of the meeting reflect a positive outlook for NRX Pharmaceuticals as it continues to navigate its growth trajectory in the pharmaceutical sector.
